Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations.

PloS one - 1 Jan 2012

Winters Mark A, Lloyd Robert M, Shafer Robert W, Kozal Michael J, Miller Michael D, Holodniy Mark

Abstract excerpt

Failure of antiretroviral regimens containing elvitegravir (EVG) and raltegravir (RAL) can result in the appearance of integrase inhibitor (INI) drug-resistance mutations (DRMs). While several INI DRMs have been identified, the evolution of EVG DRMs and the linkage of these DRMs with protease inhibitor (PI) and reverse transcriptase inhibitor (RTI) DRMs have not been studied at the clonal level. We examined the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to HIV Integrase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Integrase Inhibitors

Share to HIV Reverse Transcriptase

Share to Open Reading Frames

Share to Peptide Hydrolases

Share to Protease Inhibitors

Share to Quinolones

Source

Open in PubMed Open full text

Identifiers

PMID: 22815755
DOI: 10.1371/journal.pone.0040514
PMCID: PMC3399858

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations.PMID 22815755Read ↗

Emerging patterns and implications of HIV-1 integrase inhibitor resistanceSemantic proximity Read ↗

Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.Semantic proximity Read ↗

The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravirSemantic proximity Read ↗

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.Semantic proximity Read ↗

Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens.Semantic proximity Read ↗

HIV-1 Integrase Inhibitor Resistance and Its Clinical ImplicationsSemantic proximity Read ↗

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.Semantic proximity Read ↗

Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral TherapySemantic proximity Read ↗

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase InhibitorsSemantic proximity Read ↗

Evolution of HIV integrase resistance mutations.Semantic proximity Read ↗

Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruptionSemantic proximity Read ↗

Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.